Hillenbrand Molly, Mendy Angelico, Patel Kavya, Wilkinson Racheal, Liao Siyun, Robertson Jamie, Apewokin Senu
Department of Internal Medicine, Duke University, Durham, North Carolina, USA.
Department of Environmental and Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Open Forum Infect Dis. 2022 Mar 19;9(4):ofac045. doi: 10.1093/ofid/ofac045. eCollection 2022 Apr.
Ocular candidiasis is a known complication of candidemia. Given the poor ocular penetration of echinocandins, there is some concern that the increasing use of echinocandins may portend an increased incidence of ophthalmic complications. We examined the changing trends in antifungal prescribing patterns and the incidence of ophthalmic complications after candidemia.
Patients with blood cultures positive for species between January 2014 and June 2020 who underwent screening fundoscopic examination by an ophthalmologist were analyzed. The χ analysis was used to compare antifungal prescriptions and ocular exam findings before and after 2016. Trend analysis was also performed to assess temporal changes in prescribing practices and eye exam findings.
There were 226 candidemia cases during the study period, 129 (57.1%) of which underwent screening eye exams. From 2014 to 2015, 24 of 37 (64.5%) patients received eye-penetrating antifungals compared to 36 of 92 (39.1%) from 2016 to 2020 ( = .008). Overall, 30 of 129 (23.3%) patients had abnormal eye exams with the prevalence of abnormal findings being 7 of 37 (18.9%) before 2016 compared to 23 of 92 (25%, = .46) thereafter. A trend analysis revealed an increase in abnormal eye findings over the study period ( = .008). Of the 30 patients who had abnormal eye exams, 9 (30%) had a change in systemic antifungal therapy from echinocandins to eye-penetrating antifungals. Echinocandin use was associated with abnormal eye findings.
Prescription of eye-penetrating antifungals for candidemia has trended down since 2016. This was associated with a concomitant increase in abnormal findings on screening fundoscopy. Abnormal eye exams were not uncommon throughout our study period.
眼部念珠菌病是念珠菌血症已知的并发症。鉴于棘白菌素的眼部穿透力较差,人们担心棘白菌素使用的增加可能预示着眼科并发症的发生率上升。我们研究了念珠菌血症后抗真菌药物处方模式的变化趋势以及眼科并发症的发生率。
对2014年1月至2020年6月期间血培养念珠菌属阳性且接受眼科医生眼底镜筛查检查的患者进行分析。采用χ分析比较2016年前后的抗真菌药物处方和眼部检查结果。还进行了趋势分析,以评估处方实践和眼部检查结果的时间变化。
研究期间共有226例念珠菌血症病例,其中129例(57.1%)接受了眼部筛查检查。2014年至2015年,37例患者中有24例(64.5%)接受了具有眼部穿透力的抗真菌药物治疗,而2016年至2020年92例患者中有36例(39.1%)接受了此类治疗(P = 0.008)。总体而言,129例患者中有30例(23.3%)眼部检查异常,2016年之前37例中有7例(18.9%)检查结果异常,之后92例中有23例(25%,P = 0.46)。趋势分析显示,在研究期间眼部检查异常结果有所增加(P = 0.008)。在30例眼部检查异常的患者中,9例(30%)的全身抗真菌治疗从棘白菌素改为具有眼部穿透力的抗真菌药物。棘白菌素的使用与眼部检查异常结果相关。
自2016年以来,念珠菌血症患者使用具有眼部穿透力的抗真菌药物的处方量呈下降趋势。这与眼底镜筛查异常结果的相应增加有关。在我们的整个研究期间,眼部检查异常并不少见。